Cyteir Therapeutics (CYT) 10-K 23 Mar 23 2022 FY Annual report Financial data

Document Entity Information

Document Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2022	Mar. 20, 2023	Jun. 30, 2022
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Registrant Name	Cyteir Therapeutics, Inc.
Entity Central Index Key	0001662244
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		35,646,971
Entity Public Float			$ 69,456,355
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Security12b Title	Common Stock, par value $0.001 per share
Trading Symbol	CYT
Security Exchange Name	NASDAQ
Entity File Number	001-40499
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	45-5429901
Entity Address Address Line One	128 Spring St, Building A
Entity Address, Address Line Two	Suite 510
Entity Address City Or Town	Lexington
Entity Address State Or Province	MA
Entity Address Postal Zip Code	02421
City Area Code	857
Local Phone Number	285-4140
Document Annual Report	true
Document Transition Report	false
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2023 Annual Meeting of Stockholders within 120 days of the end of the registrant’s fiscal year ended December 31, 2022 . Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.
Auditor Name	Ernst & Young LLP
Auditor Firm ID	42
Auditor Location	Boston, MA, USA

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 147,120	$ 189,723
Prepaid expenses and other current assets	2,089	3,354
Total current assets	149,209	193,077
Property and equipment, net	1,699	2,055
Other assets	2,324	256
Total assets	153,232	195,388
Current liabilities:
Accounts payable	1,128	1,785
Accrued expenses and other current liabilities	4,187	5,726
Total current liabilities	5,315	7,511
Deferred rent, net of current portion		384
Other long term liabilities	1,631	201
Total liabilities	6,946	8,096
Commitments and contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.001 par value: 40,000,000 shares authorized as of December 31, 2022 and 2021; no shares issued and outstanding as of December 31, 2022 and 2021
Common stock, $0.001 par value: 280,000,000 shares authorized; 35,575,694 and 35,389,453 shares issued as of December 31, 2022 and 2021, respectively; 35,516,249 and 35,219,834 shares outstanding as of December 31, 2022 and 2021, respectively	35	35
Additional paid-in capital	284,365	279,310
Accumulated deficit	(138,114)	(92,053)
Total stockholders' equity	146,286	187,292
Total liabilities and stockholders' equity	$ 153,232	$ 195,388

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	40,000,000	40,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	280,000,000	280,000,000
Common stock, shares issued	35,575,694	35,389,453
Common stock, shares outstanding	35,516,249	35,219,834

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Operating expenses:
Research and development	$ 34,624	$ 30,959
General and administrative	13,546	11,300
Total operating expenses	48,170	42,259
Loss from operations	(48,170)	(42,259)
Other income:
Other income	2,109	133
Total other income	2,109	133
Net loss	$ (46,061)	$ (42,126)
Net loss per share - basic	$ (1.31)	$ (2.16)
Net loss per share - diluted	$ (1.31)	$ (2.16)
Weighted-average common stock outstanding - basic	35,272,831	19,499,292
Weighted-average common stock outstanding - diluted	35,272,831	19,499,292

Consolidated Statements of Rede

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Series A Redeemable Convertible Preferred Stock	Series B Redeemable Convertible Preferred Stock	Series C Redeemable Convertible Preferred Stock
Balance at Dec. 31, 2020	$ (48,031)	$ 2	$ 1,894	$ (49,927)
Redeemable convertible preferred stock, Shares at Dec. 31, 2020					5,817,996	55,200,000	0
Redeemable convertible preferred stock at Dec. 31, 2020					$ 5,696	$ 51,715
Balance, Shares at Dec. 31, 2020		2,044,284
Exercise of common stock options	231		231
Exercise of common stock options, Shares		94,714
Issuance of Series C redeemable convertible preferred stock, net of issuance costs of $345							$ 79,655
Issuance of Series C redeemable convertible preferred stock, net of issuance costs of $345,Shares							21,784,885
Initial public offering, net of underwriting discounts, commissions and offering costs	136,120	$ 8	136,112
Initial public offering, net of underwriting discounts, commissions and offering costs,Shares		8,285,644
Redeemable convertible preferred stock					$ (5,696)	$ (51,715)	$ (79,655)
Redeemable convertible preferred stock, Shares					(5,817,996)	(55,200,000)	(21,784,885)
Conversion of convertible preferred stock into common stock upon initial public offering	137,066	$ 25	137,041
Conversion of convertible preferred stock into common stock upon initial public offering, Shares		24,290,875
Vesting of early exercised options	567		567
Vesting of early exercised options, Shares		504,317
Stock-based compensation expense	3,465		3,465
Net loss	(42,126)			(42,126)
Balance at Dec. 31, 2021	187,292	$ 35	279,310	(92,053)
Redeemable convertible preferred stock, Shares at Dec. 31, 2021					0	0	0
Redeemable convertible preferred stock at Dec. 31, 2021
Balance, Shares at Dec. 31, 2021		35,219,834
Exercise of common stock options	$ 178		178
Exercise of common stock options, Shares	166,867	166,867
Issuance of common stock under ESPP	$ 64		64
Issuance of common stock under ESPP, Shares		19,374
Vesting of early exercised options	131		131
Vesting of early exercised options, Shares		110,174
Stock-based compensation expense	4,682		4,682
Net loss	(46,061)			(46,061)
Balance at Dec. 31, 2022	$ 146,286	$ 35	$ 284,365	$ (138,114)
Redeemable convertible preferred stock, Shares at Dec. 31, 2022					0	0	0
Redeemable convertible preferred stock at Dec. 31, 2022
Balance, Shares at Dec. 31, 2022		35,516,249

Consolidated Statements of Re_2

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Series C Redeemable Convertible Preferred Stock
Stock issuance costs	$ 345

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net loss	$ (46,061)	$ (42,126)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense	668	479
Stock-based compensation expense	4,682	3,465
Non-cash lease expense	707
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	1,189	(2,161)
Other assets		61
Accounts payable	(657)	38
Accrued expenses and other current liabilities	(3,061)	4,278
Other long term liabilities	1	2
Deferred rent		(68)
Net cash used in operating activities	(42,532)	(36,032)
Cash flows from investing activities:
Purchases of property and equipment	(312)	(1,189)
Net cash used in investing activities	(312)	(1,189)
Cash flows from financing activities:
Proceeds from issuance of preferred stock , net of issuance costs		79,655
Proceeds from issuance of common stock upon initial public offering, net of underwriting discounts, commissions and offering costs of $13,022		136,120
Proceeds from issuance of common stock under ESPP	64	0
Proceeds from exercise of stock options	178	231
Net cash provided by financing activities	242	216,006
Net (decrease) increase in cash, cash equivalents, and restricted cash	(42,602)	178,785
Cash, cash equivalents and restricted cash at beginning of period	189,979	11,194
Cash, cash equivalents and restricted cash at end of period	147,377	189,979
Supplemental disclosure of cash flows
Property and equipment purchases in accounts payable		58
Supplemental disclosure of noncash financing activities
Vesting of early exercised options	131	567
Conversion of preferred stock to common stock upon initial public offering		137,066
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	147,120	189,723
Restricted cash (included in other assets)	$ 257	$ 256
Restricted Cash and Cash Equivalents, Noncurrent, Asset, Statement of Financial Position [Extensible List]	Other assets	Other assets
Total cash, cash equivalents, and restricted cash	$ 147,377	$ 189,979

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Statement of Cash Flows [Abstract]
Underwriting discounts, commissions and offering costs	$ 13,022

Nature of the Business

Nature of the Business	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Nature of the Business	1. Nature of the business Cyteir Therapeutics, Inc., (the “Company”) is a clinical-stage oncology company that is focused on the development of CYT-0851, an oral investigational drug candidate that inhibits monocarboxylate transporters. Cyteir’s current priority in CYT-0851 development is in combination with capecitabine or gemcitabine in a Phase 1/2 clinical study, including patients with advanced ovarian cancer or other solid tumors, respectively. Through 2022, the Company used its expertise in DNA damage response biology and a disciplined approach to select targets for other novel, differentiated programs with the aim of building a patient-centric portfolio of effective cancer therapies. In January 2023, the Company announced a strategic prioritization that included the discontinuation of these preclinical efforts. The Company was formed as a Delaware corporation on June 4, 2012, pursuant to the General Corporation Law of the State of Delaware. The Company has a principal office in Lexington, Massachusetts. Initial Public Offering ("IPO") On June 22, 2021, the Company completed an IPO in which the Company issued and sold 7,400,000 of its common stock, at a public offering price of $ 18.00 per share, resulting in gross proceeds of $ 133.2 million. The Company received $ 121.6 million in net proceeds after deducting underwriting discounts, commissions and offering costs. Upon closing of the IPO, all of the then-outstanding shares of convertible preferred stock automatically converted into 24,290,875 shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were no shares of convertible preferred stock outstanding. On July 1, 2021, the underwriters of the IPO partially exercised their over-allotment option by purchasing an additional 885,644 shares of our common stock at a public offering price of $ 18.00 per share for gross proceeds of $ 15.9 million prior to deducting underwriting discounts, commissions, and other offering expenses. The Company received $ 14.5 million in net proceeds after deducting underwriting discounts, commissions and offering costs. The remainder of the underwriters' over-allotment option expired unexercised. Reverse Stock Split On June 11, 2021, the Company effected a 1 -for-3.4088 reverse stock split of the Company’s common stock and adjusted the ratio at which the Company’s preferred stock was convertible into common stock, as well as the number of shares under the 2012 Stock Incentive Plan and the Company’s Amended and Restated Certificate of Incorporation, as well as the share amounts of restricted stock grants under the plan and the number of options and exercise prices of options under the plan as a result of the 1 -for-3.4088 reverse stock split. All common shares, stock options, and per share information presented in the accompanying consolidated financial statements and notes thereto have been adjusted, where applicable, to reflect the reverse stock split on a retroactive basis for all periods presented. The per share par value and authorized number of shares of the Company’s common stock were not adjusted as a result of the split. Liquidity The Company has incurred negative cash flows since inception and has funded its operations primarily with proceeds from the sale of redeemable convertible preferred stock and the IPO. As of December 31, 2022, the Company had cash and cash equivalents of $ 147.1 million and an accumulated deficit of $ 138.1 million. The Company expects its operating losses and negative operating cash flows to continue into the foreseeable future as it continues to expand its research and development efforts. The Company expects that its cash and cash equivalents as of December 31, 2022 will be sufficient to fund its operating expenses and capital expenditure requirements for at least twelve months from the date these consolidated financial statements are available to be issued. The Company will need additional funding to support its planned operating activities. There can be no assurances, however, that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. If the Company is unable to obtain sufficient funding, it could be required to delay its development efforts, limit activities and reduce research and development costs, which could adversely affect its business prospects. COVID-19 considerations The development of the Company’s product candidates could be disrupted and materially adversely affected in by a pandemic, epidemic or outbreak of an infectious disease, such as the ongoing COVID-19 pandemic. The ongoing COVID-19 pandemic and the measures taken by the governments of countries affected by it could disrupt the supply chain and the manufacture or shipment of both drug substance and finished drug product for the Company’s product candidates for preclinical testing or clinical trials, cause diversion of healthcare resources away from the conduct of preclinical and clinical trial matters to focus on pandemic concerns, limit travel in a manner that interrupts key trial activities, such as trial site initiations and monitoring, delay regulatory filings with regulatory agencies in affected areas or adversely affect the Company’s ability to obtain regulatory approvals. These disruptions could also affect other facets of the Company’s business, including, but not limited to, the Company’s ability to recruit employees from outside of the United States, the ability of the Company’s CROs to conduct clinical trials and preclinical studies in countries outside of the United States, the Company’s ability to import materials from outside of the United States, including raw materials required to manufacture its drug candidates, the Company’s ability to export materials to its CROs and other third-parties located outside of the United States, the Company’s ability to identify suitable clinical sites or open those sites for enrollment due to competing business needs, the Company’s ability to enroll patients due to their fear of coming into medical facilities and their perceived risk of becoming infected at such facilities, and the Company’s ability to monitor the clinical data generated at its clinical sites, required for completion of clinical trials.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of significant accounting policies Basis of presentation and consolidation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements include Cyteir Securities Corporation, which was incorporated as a Massachusetts Security Corporation. All intercompany accounts, transactions and balances have been eliminated in consolidation. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates. Segment information Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one operating segment. The Company’s focus is the research and development of small molecule therapeutics that target DNA repair in cancer. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purpose of allocating resources. All of the Company’s long-lived assets are held in the United States. Cash and cash equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include standard checking accounts and amounts held in money market funds. Restricted cash Cash accounts with any type of restriction are classified as restricted cash. The Company has restricted cash deposits with a bank, which serve as collateral for a letter of credit issued to the landlord of the Company’s leased facility for a security deposit. The Company classified this amount as restricted cash in the accompanying consolidated balance sheets within non-current assets as of December 31, 2022 and 2021 . Concentration of credit risk and off-balance sheet risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and restricted cash. The Company may maintain deposits in federally insured financial institutions and limits its exposure to cash risk by keeping amounts in each institution under the federally insured limits and by placing its cash with high credit quality financial institutions, further the Company has not experienced any losses on these deposits. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimize its exposure to concentration of credit risk. The Company has no financial instruments with off-balance-sheet risk of loss and has not experienced any losses on such accounts. The Company is dependent on third-party contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”) with whom they do business. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements of active pharmaceutical ingredients and formulated drugs in order to perform research and development activities in its programs. The Company also relies on a limited number of third-party contract research organizations to perform research and development activities on its behalf. These programs could be adversely affected by significant interruption from these providers. Comprehensive loss Comprehensive loss includes net loss as well as other changes in stockholders’ equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2022 and 2021 , there was no difference between net loss and comprehensive loss. Leases Prior to January 1, 2022, the Company accounted for leases in accordance with Accounting Standards Codification (“ASC”) 840, Leases. At lease inception, the Company determined if an arrangement was an operating or capital lease. For operating leases, the Company recognized rent expense, inclusive of rent escalations and lease incentives, on a straight-line basis over the lease term. Effective January 1, 2022, the Company adopted ASC 842, Leases (“ASC 842”), and elected to apply the modified retrospective transition approach using the effective date as the initial date of application. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. At the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease and recognizes a right-of-use (“ROU”) asset and a current and non-current lease liability, as applicable, on the consolidated balance sheet if the lease has a term greater than one year. As permitted under ASC 842, the Company has made an accounting policy election, for all classes of underlying assets, to not recognize ROU assets and lease liabilities for leases having a term of twelve months or less. When it determines the appropriate classification and accounting for a lease arrangement, the Company typically only considers the committed lease term. Options to extend a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will either renew or not cancel, respectively. At the lease commencement date, the operating lease liability and corresponding ROU asset are recorded at the present value of future lease payments over the expected remaining lease term using the discount rate implicit in the lease, if it is readily determinable, or the Company’s incremental borrowing rate. The Company’s incremental borrowing rate reflects the fixed rate at which the Company could borrow the amount of lease payments in the same currency on a collateralized basis, for a similar term in a similar economic environment. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments, incentives received, or initial direct costs. The Company enters into contracts that contain both lease and non-lease components. Non-lease components include costs that do not provide a right-to-use a leased asset but instead provide a service, such as maintenance costs. After its adoption of ASC 842, the Company has elected to combine the lease and non-lease components together as a single lease component for all existing classes of underlying assets. Variable costs associated with the lease, such as maintenance and utilities, are not included in the measurement of right-to-use assets and lease liabilities but rather are expensed when the events determining the amount of variable consideration to be paid have occurred. Upon its adoption of ASC 842 on January 1, 2022 , the Company recorded a lease liability and its corresponding ROU asset based on the present value of lease payments over the remaining lease term. The adoption of ASC 842 resulted in the recognition of an operating lease liability of $ 3.2 million and ROU assets of $ 2.8 million, with the offset attributed to the net derecognition of prepaid rent and the unamortized deferred rent liability, inclusive of tenant improvement allowances on the Company’s balance sheet as of January 1, 2022. The adoption of ASC 842 did no t have a material impact on the Company’s statements of operations and comprehensive loss or statements of cash flows. Property and equipment, net Property and equipment are stated at cost, less accumulated depreciation. Costs of major additions and betterments are capitalized. Maintenance and repairs which do not improve or extend the life of the respective assets are charged to expense as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from five to seven years . Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to the consolidated statements of operations. Property and equipment to be disposed of are carried at fair value less costs to sell. The estimated useful lives of the Company’s property and equipment are as follows: Estimated useful life (in years) Laboratory equipment and computer equipment 5 years Furniture 5 - 7 years Leasehold improvements Lesser of asset useful life or lease term Impairment of long-lived assets The Company accounts for long-lived assets in accordance with ASC Topic 360, Property, Plant, and Equipment (“ASC 360”). ASC 360 requires companies to: (i) recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and (ii) measure an impairment loss as the difference between the carrying amount and the fair value of the asset. The Company tests long-lived assets to be held and used, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of assets or asset groups may not be fully recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their fair values. The Company has not recognized any impairment losses during the years ended December 31, 2022 and 2021 . Fair value measurements ASC Topic 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company has no assets or liabilities classified as Level 3 on its consolidated balance sheets as of December 31, 2022 and 2021. Financial instruments consist of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature. Deferred financing costs The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred financing costs until such financings are closed. After consummation of the equity financing, these costs are presented in the consolidated balance sheets as a direct reduction from the carrying amount of the respective equity instrument issued. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. No amounts were recorded as of December 31, 2022 or December 31, 2021 . Research and development costs Research and development costs are charged to expense as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including personnel-related costs, stock-based compensation, facilities, research-related overhead, clinical trial costs, contracted services, research-related manufacturing, license fees and other external costs. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received. Accrued research and development expenses The Company has entered into various research and development contracts. The payments under these contracts are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes the progress of the research and development activities, including the phase or completion of events, invoices received and contracted costs. Significant judgements and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs. Patent costs All patent-related costs incurred in connection with filing and prosecuting patent applications such as direct application fees, and legal and consulting expenses are expensed as incurred due to the uncertainty about the recovery of the expenditure. Patent-related costs are classified as general and administrative expenses within the Company’s consolidated statements of operations. Redeemable convertible preferred stock The Company has classified redeemable convertible preferred stock (“preferred stock”) as temporary equity in the accompanying consolidated balance sheets due to terms that allow for redemption of the shares upon certain events that are outside of the Company’s control. The Company did no t have any preferred stock outstanding as of December 31, 2022 . Stock-based compensation The Company accounts for all share-based payment awards granted to employees and non-employees as stock-based compensation expense at fair value. The Company’s share-based payments include stock options and grants of common stock, including common stock subject to vesting. The measurement date for employee awards is the date of grant, and stock-based compensation costs are recognized as expense over the employees’ requisite service period, which is the vesting period, on a straight-line basis. Prior to the adoption of Accounting Standards Update (“ASU”) No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU No. 2018-07”) on January 1, 2020 , the measurement date for non-employee awards was generally the date the services were completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. Since the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of grant without changes in the fair value of the award. There was no material impact as a result of adopting this new standard. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on a straight-line basis. Stock-based compensation expense is classified in the accompanying consolidated statements of operations based on the function to which the related services are provided. Forfeitures are recorded as they occur. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. Since there is limited historical data of the Company’s share price on the public market, the Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of representative companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company’s common shares and participating securities. The Company’s preferred stock contained participation rights in any dividend paid by the Company and was deemed to be a participating security. Net loss attributable to common stockholders is allocated to each share on an as-converted basis as if all of the earnings for the period had been distributed. The participating securities did not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. In June 2021, upon the closing of the IPO, all outstanding shares of the Company's preferred stock automatically converted into shares of the Company's common stock. Prior to this conversion, the Company calculated diluted net loss per share using the more dilutive of (a) the two-class method or (b) the if-converted method. The Company allocated earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2022 and 2021 . Income taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or the Company’s tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established. The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a “more likely than not” threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are no unrecognized tax benefits included in the Company’s consolidated balance sheet as of December 31, 2022 and 2021 . The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties in its Statements of Operations since inception. Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with certain new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued Accounting Standards Update No. 2019-12 (ASU 2019-12) Simplifying the Accounting for Income Tax . The standard contains several provisions that reduce financial statement complexity including removing the exception to the incremental approach for intra-period tax expense allocation when a company has a loss from continuing operations and income from other items not included in continuing operations. The new guidance is effective for the year beginning January 1, 2022 with optional adoption prior to the effective date, and did not have a material impact to the Company’s consolidated financial statements.

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurement	3. Fair value measurement The following tables present information about the Company’s financial assets measured at fair value on a recurring basis (in thousands): December 31, 2022 Assets Total Quoted prices in Significant other observable inputs Significant other Cash equivalents: Money market funds $ 146,870 $ 146,870 $ — $ — Total assets $ 146,870 $ 146,870 $ — $ — December 31, 2021 Assets Total Quoted prices in Significant other observable inputs Significant other Cash equivalents: Money market funds $ 189,488 $ 189,488 $ — $ — Total assets $ 189,488 $ 189,488 $ — $ — During the years ended December 31, 2022 and 2021 , there were no transfers between levels. The fair values of the Company’s cash equivalents, consisting of its money market funds, are based on quoted market prices in active markets without any valuation adjustment.

Prepaid Expenses and Other Curr

Prepaid Expenses and Other Current Assets	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets	4. Prepaid expenses and other current assets Prepaid expenses and other current assets consisted of the following (in thousands): December 31, 2022 2021 Prepaid research and development expenses $ 786 $ 1,549 Prepaid insurance 982 1,397 Prepaid other 321 408 Total $ 2,089 $ 3,354

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	5. Property and equipment, net Property and equipment, net consisted of the following (in thousands): December 31, 2022 2021 Laboratory and computer equipment $ 1,846 $ 1,541 Leasehold improvements 1,675 1,668 Total property and equipment 3,521 3,209 Less: accumulated depreciation and amortization ( 1,822 ) ( 1,154 ) Property and equipment, net $ 1,699 $ 2,055 Depreciation and amortization expense related to property and equipment for the years ended December 31, 2022 and 2021 was $ 0.7 million and $ 0.5 million, respectively.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued Expenses and Other Current Liabilities	6. Accrued expenses and other current liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): December 31, 2022 2021 Accrued research and development expenses $ 1,356 $ 3,448 Accrued compensation 1,510 1,660 Accrued other 432 618 Operating lease liabilities 889 — Total accrued expenses and other current liabilities $ 4,187 $ 5,726

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	12 Months Ended
	Dec. 31, 2022
Temporary Equity Disclosure [Abstract]
Redeemable Convertible Preferred Stock	7. Redeemable convertible preferred stock The Company issued Series A redeemable convertible preferred stock (“Series A Preferred Stock”), Series B redeemable convertible preferred stock ("Series B Preferred Stock), and Series C redeemable preferred stock ("Series C Preferred Stock). Upon issuance of each class of convertible preferred stock, the Company assessed the embedded conversion and liquidation features of the shares and determined that such features did not require the Company to separately account for these features. The Company also concluded that no beneficial conversion feature existed on the issuance date of each class of convertible preferred stock. In February 2021, the Company completed the sale of an aggregate of 21,784,885 shares of the Series C preferred stock at a purchase price of $ 3.67 per share for an aggregate purchase price of $ 79,999,980 . On June 22, 2021, upon closing of the Company's IPO, all of the then-outstanding shares of preferred stock automatically converted into 24,290,875 shares of common stock. There were no outstanding shares of preferred stock at December 31, 2022. Significant terms of the Series A Preferred Stock and Series B Preferred Stock (collectively, “Preferred Stock”) were as follows: Voting The holder of each share of Preferred Stock was entitled to one vote for each share of common stock into which it would convert and to vote with the common stock on all matters. As long as a minimum number of Series A Preferred Stock and Series B Preferred Stock was outstanding, the holders of the Series A Preferred Stock and Series B Preferred Stock were entitled to elect three directors and the approval of certain actions requires a majority of the Preferred Stockholders. Conversion As of December 31, 2020, the shares of Preferred Stock were convertible into shares of common stock, at the conversion price in effect at the time of such conversion, which was initially one -for-one subject to adjustment for certain potential non-dilutive transactions. The conversion could be initiated by the holder at any time or was mandatory (a) at any time upon the written consent of the holders of a majority of the outstanding shares of the Preferred Stock or (b) immediately upon the closing of a qualified public offering of gross proceeds to the Company of at least $ 50,000,000 . In the event that any holder of shares of Series B Preferred Stock did not purchase the full amount of such holder’s preferred stock tranche obligation, then each share of Series B Preferred Stock held by such holder automatically converted into shares of common stock at a ratio of 1 /10th of the applicable conversion ratio. As all tranche obligations were completed as of July 2019, this conversion feature expired unexercised. Dividends The holders of the Preferred Stock were entitled to receive dividends at the rate of 8 % of the applicable original issue price per annum, as potentially adjusted for certain non-dilutive transactions. Dividends would accrue whether or not declared, would not be cumulative or compounded and would be payable only when, as and if declared by the Board of Directors (the “Board”) and in preference and in priority to any dividends on common stock. There were no dividends declared by the Board. Liquidation preference In the event of any liquidation, dissolution, or winding up of the Company (“Liquidation Event”), the holders of Preferred Stock were entitled to receive prior and in preference to the holders of common stock, an amount equal to an amount per share equal to the greater of the original issue price, as potentially adjusted for certain non-dilutive transactions, plus all declared and unpaid dividends on the Preferred Stock or the price per share that would be received if the Preferred Stock were converted to common stock. If the assets and funds available to be distributed to all holders of Preferred Stock were insufficient to permit the payment, in full, of any of the liquidation preferences, then the entire assets and funds legally available for distribution to holders of the Preferred Stock would be distributed ratably among the holders of Preferred Stock, acting as a single class, at the time outstanding, ratably in proportion to the full amounts to which they would otherwise be respectively entitled. After the payment of the full liquidation preference of the Preferred Stock as set forth above, the remaining assets of the Company legally available for distribution in such Liquidation event would be distributed ratably to the holders of shares of common stock. Redemption The Company has determined that all series of preferred stock were redeemable, based on the Certificate of Incorporation that states upon the occurrence of a deemed liquidation event, the holders of preferred stock were entitled to receive cash or other assets.

Common Stock

Common Stock	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Common Stock	8. Common stock The voting, dividend and liquidation rights of the holders of the Company’s common stock were subject to and qualified by the rights, powers and preferences of the holders of the preferred stock as set forth above. The holders of the common stock are entitled to one vote for each share of common stock held submitted to a vote of stockholders, and there are not any cumulative voting rights. Holders of common stock are entitled to receive proportionately any dividends as may be declared by our board of directors, subject to any preferential dividend rights of any series of preferred stock that we may designate and issue in the future. As of December 31, 2022 and 2021, the Company has reserved the following shares of common stock for the potential conversion of outstanding preferred stock and exercise of stock options: December 31, 2022 2021 Options to purchase common stock 3,460,897 2,778,963 Remaining shares reserved for future issuance 5,706,345 5,670,560 Total 9,167,242 8,449,523

Stock-based Compensation

Stock-based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	9. Stock-based compensation 2012 stock incentive plan The 2012 Stock Incentive Plan (the “2012 Plan”) provides for the issuance of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards and other stock awards. Recipients of stock options or stock appreciate rights shall be eligible to purchase shares of the Company’s common stock at an exercise price equal to the estimated fair market value of such stock on the date of grant. The exercise price may be less than fair market value if the stock award is granted pursuant to an assumption or substitution for another stock award in the event of a merger or sale of the Company. The maximum term of options granted under the 2012 Plan is ten years , and stock options typically vest over a four-year period. The Board may assign vesting terms to the stock option grants as deemed appropriate. The Company also has the right of refusal to purchase any proposed disposition of shares issued under the 2012 Plan. The 2012 Plan allows for early exercise of all stock option grants if authorized by the Board at the time of grant. The shares of common stock issued from the early exercise of stock options are restricted and vest over time. The Company has the option to repurchase any unvested shares at the original purchase price upon any voluntary or involuntary termination. At the discretion of the Board, unvested shares held by employees may accelerate vesting in the event of a change of control of the Company unless assumed or substituted by the acquirer or surviving entity. The 2012 Plan, as amended, provides for the issuance of up to 6,941,421 shares of common stock as of December 31, 2022 , of which 2,732,632 shares of common stock remained available for future grant under the 2012 Plan upon the effectiveness of the 2021 Equity Incentive Plan (the “2021 Plan”) and were made available for future issuance under the 2021 Plan. 2021 Equity Incentive Plan In June 2021, the Company’s board of directors adopted, and in June 2021 the Company’s stockholders approved, the 2021 Plan, which became effective immediately prior to the effectiveness of the registration statement for the initial public offering. The 2021 Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock units and other stock-based awards. Upon effectiveness of the 2021 Plan, the number of shares of common stock reserved for issuance under the 2021 Plan was 5,932,632 , which represents 3,200,000 shares along with 2,732,632 shares of common stock reserved for issuance under the 2012 Plan that remained available for grant under the 2012 Plan immediately prior to the effectiveness of the 2021 Plan. Shares of our common stock subject to outstanding awards granted under the 2012 Plan that expire unexercised or are terminated, surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right will become available for issuance under the 2021 Plan. The 2021 Plan includes an "evergreen" provision, which provides for an annual increase to be added on January 1st of each year beginning in 2022 and continuing through and including 2031 by the lesser of (i) 5 % of the number of shares of Stock outstanding as of such date and (ii) an amount determined by the board of directors. Upon adoption of the 2021 Plan, the Company ceased the grant of additional awards under the 2012 Plan. At December 31, 2022 , 5,706,345 shares of common stock remained available for future grant under the 2021 Plan. 2021 Employee Stock Purchase Plan In June 2021, the Company’s board of directors adopted, and the Company’s stockholders approved, the 2021 Employee Stock Purchase Plan (the “ESPP”), which became effective immediately prior to the effectiveness of the registration statement for the initial public offering. The ESPP is administered by the Company’s board of directors or by a committee appointed by the board of directors. The ESPP initially provides participating employees with the opportunity to purchase up to an aggregate of 300,000 shares of common stock. The number of shares of common stock reserved for issuance under the ESPP will automatically increase on January 1st of each year beginning in 2022 and continuing through and including 2031 by the least of (i) 1 % of the number of shares of Stock outstanding as of such date, (ii) 600,000 shares of Stock and (iii) the number of shares of Stock determined by the Board on or prior to such date for such year, up to a maximum of 6,300,000 shares in the aggregate. The ESPP allows eligible employees to authorize payroll deductions of between 1% and 15% of their regular base salary or wages to be applied toward the purchase of shares of the Company's common stock on the last trading day of the offering period, subject to certain limitations contained in the ESPP. Participating employees will purchase shares of the Company's common stock at a discount of 15% on the lesser of the closing price of the Company's common stock on the Nasdaq Global Select Market (i) on the first trading day of the offering period or (ii) the last trading day of the offering period. The Company utilizes the Black Scholes option pricing model to compute the fair market value of the shares subject to outstanding options under the ESPP and compensation expense is recognized over the offering period. Participation in the ESPP is voluntary. Eligible employees become participants in the ESPP by enrolling in the plan and authorizing payroll deductions in accordance with the terms of the ESPP. At the end of each offering period, accumulated payroll deductions are used to purchase the Company’s shares at the discounted price. The Company makes no contributions to the ESPP. A participant may withdraw from the ESPP or reduce contributions to the ESPP during an offering period. If the participant elects to withdraw during an offering period, all contributions are refunded as soon as administratively practicable. If a participant elects to withdraw during an offering period, the participant may not re-enroll in the current offering but may elect to participate in future offerings, subject to the terms of the ESPP. Only whole shares of the Company may be purchased under the ESPP. The Company issued 19,374 common shares under the ESPP during the year ended December 31, 2022 at an average price per share of $ 3.32 . Cash received from purchases under the ESPP for the year ended December 31, 2022 was $ 0.1 million. The Company recognized $ 0.1 million of compensation expense for the ESPP during the year ended December 31, 2022. Early exercise of unvested stock options Shares purchased by employees pursuant to the early exercise of stock options are not deemed, for accounting purposes, to be outstanding shares until those shares vest according to their respective vesting schedules. Cash received from employee exercises of unvested options is included in long-term liabilities on the consolidated balance sheets. Amounts recorded are reclassified to common stock and additional paid-in capital as the shares vest. As of December 31, 2022 and 2021 , there were 59,445 and 169,919 unvested shares related to early exercises of stock options, respectively. Stock option valuation The assumptions that the Company used in the Black Scholes option-pricing model to determine the grant date fair value of stock options granted were as follows: December 31, 2022 2021 Risk-free interest rate range%-% 1.89 %- 4.23 % 0.75 %- 1.35 % Dividend yield% 0.0 % 0.0 % Expected life of options (years) 6.0 5.5 - 6.1 Volatility rate range%-% 92.4 %- 93.3 % 93.6 %- 97.1 % The following table summarizes the Company’s stock option activity under the 2012 and 2021 Plan: Number of Weighted average Weighted average Aggregate intrinsic Outstanding as of December 31, 2021 2,778,963 $ 5.80 8.76 $ 17,102 Granted 1,054,559 4.59 Exercised ( 166,867 ) 1.06 Forfeited or cancelled ( 205,758 ) 6.86 Outstanding as of December 31, 2022 3,460,897 $ 5.60 8.23 $ 375 Options vested and exercisable as of December 31, 2022 1,454,830 $ 5.90 7.81 $ 214 As of December 31, 2022 , there was $ 7.4 million of unrecognized stock-based compensation expense related to the share-based compensation arrangements under the 2012 and 2021 Plans. The Company expects to recognize this amount over a weighted-average period of 2.0 years. The aggregate intrinsic value of options is calculated as the difference between the exercise price of the stock options and the fair value of the Company’s common stock for those stock options that had exercise prices lower than the fair value of the common stock as of the end of the reporting period. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The weighted-average grant date fair value of the Company’s stock options granted during the years ended December 31, 2022 and 2021 was $ 3.48 and $ 6.87 , respectively. The total fair value of options vested during the years ended December 31, 2022 and 2021 , was $ 5.6 million an d $ 2.1 million, respectively. Stock-based compensation expense Stock-based compensation expense included in the Company’s consolidated statements of operations is as follows (in thousands): December 31, 2022 2021 Research and development $ 1,861 $ 1,154 General and administrative 2,821 2,311 Total stock-based compensation expense $ 4,682 $ 3,465

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Income Taxes	10. Income taxes Loss before provision for income taxes was as follows (in thousands): December 31, 2022 2021 United States $ ( 46,034 ) $ ( 42,129 ) Total $ ( 46,034 ) $ ( 42,129 ) No current or deferred provisions for income taxes were recorded as of December 31, 2022 and 2021, respectively due to losses incurred in both periods. The following reconciles the differences between income taxes computed at the federal statutory rate and the provision for income taxes: December 31, 2022 2021 Federal statutory income tax rate 21.0 % 21.0 % State taxes 6.8 % 6.8 % Valuation allowance ( 29.3 )% ( 29.5 )% Tax Credits 2.4 % 2.5 % Stock Based Compensation ( 1.1 )% ( 0.4 )% Other 0.2 % ( 0.4 )% Total —% —% Certain amounts in prior year's financial statements have been reclassified to conform to the current presentation. The reclassifications had no effect on the reported net loss. Deferred tax assets and liabilities reflect the net tax effects of net operating loss ("NOL") and tax credit carryforwards and temporary differences between the carrying amount of assets and liabilities for financial reporting and the amounts used for tax purposes. Significant components of the Company’s deferred tax assets and liabilities were as follows (in thousands): December 31, December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 27,219 $ 24,239 Tax credits carryforward 4,613 3,163 Deferred rent — 24 Accrued expenses 366 454 Stock-based compensation 1,255 402 Lease Liability 666 — R&D Capitalization 7,992 — Total deferred tax assets 42,111 28,282 Valuation allowance ( 40,902 ) ( 27,413 ) Deferred tax assets $ 1,209 $ 869 Deferred tax liabilities: Depreciation $ ( 285 ) $ ( 433 ) Prepaid expenses ( 349 ) ( 396 ) Stock-based compensation ( 14 ) ( 40 ) ROU Asset ( 561 ) — Total deferred tax liabilities ( 1,209 ) ( 869 ) Net deferred tax assets $ — $ — The Company has evaluated the positive and negative evidence bearing upon its ability to realize the deferred tax assets. Management has considered the Company’s history of cumulative net losses incurred since inception and has concluded that it is more likely than not that the Company will not realize the benefits of the deferred tax assets. Accordingly, a full valuation allowance has been established against the net deferred tax assets as of December 31, 2022 and 2021 . Management reevaluates the positive and negative evidence at each reporting period. Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2022 and 2021 related primarily to the increase in net operating loss carryforwards, capitalized research and development costs, and Research and Development credits and were as follows (in thousands): December 31, December 31, 2022 2021 Valuation allowance at beginning of year $ 27,413 $ 14,983 Increases recorded to income tax provision 13,489 12,430 Valuation allowance at end of year $ 40,902 $ 27,413 As of December 31, 2022 , the Company had federal net operating loss carryforwards of approximately $ 100.1 million, including $95.5 million of which may be available to offset future income tax liabilities indefinitely, while $ 4.6 million of carryforwards that were in existence as of December 31, 2017 may offset future income tax liabilities up through 2037 . The Company had state net operating loss carryforwards of approximately $ 98.3 million to offset future state taxable income which will expire at various time through 2042 . The Company also had U.S Federal research and development tax credit carryforwards of $ 4.1 million available to offset future U.S. federal income taxes. As of December 31, 2022 , the Company had state tax credit carryforwards of $ 1.7 million which expire at various times through 2037 and may be used to offset future state taxable income. The Company's NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has not completed a study to assess whether a change of ownership has occurred, or whether there have been multiple ownership changes since its formation, due to the significant cost and complexity associated with such a study. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position. The Company has not, as of yet, conducted a study of research and development credit carryforwards. Such a study, once undertaken by the Company, may result in an adjustment to the Company’s research and development credit carryforwards; however, until a study is completed and any adjustment is known, no amounts are being presented as an uncertain tax position. A full valuation allowance has been provided against the Company’s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the valuation allowance. Thus, there would be no impact to the balance sheet or statement of operations if an adjustment is required. The Company accounts for Uncertainty in Income Taxes under the provisions of ASC 740 which defines the thresholds for recognizing the benefits of tax return positions in the financial statements as "more likely than not" to be sustained by the taxing authority. The tax benefit is measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. As of December 31, 2022 and 2021 , the Company has recorded $ 0.9 million and $ 0.6 million respectively, in unrecognized tax benefits. The Company's policy is to recognize both interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of December 31, 2022, and 2021 , respectively, there were no interest or penalties associated with unrecognized tax benefits. The following is a reconciliation of the total amount of unrecognized tax benefits (in thousands): December 31, 2022 2021 Unrecognized benefit at beginning of year $ 582 $ 315 Additions/reductions for tax positions related to the current year 274 267 Unrecognized benefit at end of year $ 856 $ 582 The federal and state income tax returns are generally subject to examinations for the tax years ended December 31, 2019 through December 31, 2022. To the extent the Company has tax attribute carryforwards, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities to the extent utilized in a future period. The Company files income tax returns in the U.S. federal and various state jurisdictions. There are currently no federal or state audits in process.

Net Loss per Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	11. Net loss per share The Company’s potentially dilutive securities, which include preferred stock and stock options, have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following shares from the computation of diluted net loss per share attributable to common stockholders as of December 31, 2022 and 2021 because including them would have had an anti-dilutive effect: December 31, 2022 2021 Options to purchase common stock 3,460,897 2,778,963 Unvested shares from early exercises 59,445 169,619

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	12. Commitments and contingencies Legal proceedings From time to time, in the ordinary course of business, the Company is subject to litigation and regulatory examinations as well as information gathering requests, inquiries and investigations. As of December 31, 2022 , there were no matters which would have a material impact on the Company’s financial results.

Leases

Leases	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Leases	13. Leases Operating Lease In August 2018, the Company entered into an operating lease agreement for office and laboratory space within the building complex located in Lexington, Massachusetts. The lease commenced in November 2018, and as subsequently amended, is approximately 14,636 rentable square feet (“Original Premises”) and has a maturity date of October 31, 2023 . In July 2021, the Company entered into the second amendment of the lease and expanded the office space by approximately 5,531 square feet (the “Expansion Premises”), and extended the maturity date to December 31, 2025 for both the Original Premises and Expansion Premises. Lease payments are made monthly, subject to a 3 % annual rent increase, and the Company pays for its proportionate share of building operating costs such as maintenance, utilities, and insurance that are treated as variable costs and excluded from the measurement of the lease. The following table summarizes the presentation of the Company's operating leases on its consolidated balance sheet: Leases Balance sheet classification December 31, Assets Operating lease assets Other assets $ 2,066 Liabilities Current Operating lease liabilities Accrued expenses and other current liabilities $ 889 Noncurrent Operating lease liabilities Other long term liabilities 1,560 Total lease liabilities $ 2,449 The components of lease cost under ASC 842 included in the Company’s consolidated statement of operations for the year ended December 31, 2022 were as follows: Year Ended December 31, Lease Cost Statement of operations classification 2022 Operating lease cost Research and development $ 593 Operating lease cost General and administrative 165 Variable lease cost Research and development 437 Variable lease cost General and administrative 122 Total lease cost $ 1,317 The weighted average remaining lease term and weighted average discount rate of the operating leases was 3.0 years and 5.0 %, respectively, at December 31, 2022 . The Company made cash payments for amounts included in the measurement of operating liabilities of $ 0.8 million for the year ended December 31, 2022. Future minimum lease payments under non-cancellable operating leases as of December 31, 2022 are as follows (in thousands): Maturity of lease liabilities Amount 2023 $ 910 2024 883 2025 833 Total lease payments 2,626 Less: interest ( 177 ) Present value of operating lease liabilities $ 2,449

Employee Benefit Plans

Employee Benefit Plans	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Employee Benefit Plans	14. Employee benefit plans The Company has a 401(k) retirement plan for its employees, which is designed to be qualified under Section 401(k) of the Internal Revenue Code. Eligible employees are permitted to contribute to the 401(k) plan within statutory and 401(k) plan limits. The Company implemented a matching contribution in 2022 and has made $ 0.3 million matching contributions during the year ended December 31, 2022 .

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events On January 19, 2023, the Company announced a strategic prioritization of clinical development of CYT-0851, which included the discontinuation of preclinical efforts and a workforce reduction by approximately 70 % of the Company's workforce. The Company expects to complete the reduction in its workforce in the first quarter of 2023. The Company estimates that, in connection with these changes, it will incur aggregate charges of approximately $ 2.5 million to $ 3 million, all of which are anticipated to result in future cash expenditures, primarily for employee severance and benefit costs, the majority of which are expected to be incurred in the first quarter of 2023.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation and Consolidation	Basis of presentation and consolidation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). The consolidated financial statements include Cyteir Securities Corporation, which was incorporated as a Massachusetts Security Corporation. All intercompany accounts, transactions and balances have been eliminated in consolidation.
Use of Estimates	Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Changes in estimates and assumptions are reflected in reported results in the period in which they become known. Actual results could differ from those estimates.
Segment Information	Segment information Operating segments are defined as components of an enterprise for which separate and discrete information is available for evaluation by the chief operating decision-maker in deciding how to allocate resources and assess performance. The Company has one operating segment. The Company’s focus is the research and development of small molecule therapeutics that target DNA repair in cancer. The Company’s chief operating decision maker, its Chief Executive Officer, manages the Company’s operations on a consolidated basis for the purpose of allocating resources. All of the Company’s long-lived assets are held in the United States.
Cash and Cash Equivalents	Cash and cash equivalents The Company considers all highly liquid investments purchased with original maturities of 90 days or less at acquisition to be cash equivalents. Cash and cash equivalents include standard checking accounts and amounts held in money market funds.
Restricted Cash	Restricted cash Cash accounts with any type of restriction are classified as restricted cash. The Company has restricted cash deposits with a bank, which serve as collateral for a letter of credit issued to the landlord of the Company’s leased facility for a security deposit. The Company classified this amount as restricted cash in the accompanying consolidated balance sheets within non-current assets as of December 31, 2022 and 2021 .
Concentration Risk, Credit Risk And Off-balance Sheet Risk	Concentration of credit risk and off-balance sheet risk Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, and restricted cash. The Company may maintain deposits in federally insured financial institutions and limits its exposure to cash risk by keeping amounts in each institution under the federally insured limits and by placing its cash with high credit quality financial institutions, further the Company has not experienced any losses on these deposits. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimize its exposure to concentration of credit risk. The Company has no financial instruments with off-balance-sheet risk of loss and has not experienced any losses on such accounts. The Company is dependent on third-party contract research organizations (“CROs”) and contract manufacturing organizations (“CMOs”) with whom they do business. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements of active pharmaceutical ingredients and formulated drugs in order to perform research and development activities in its programs. The Company also relies on a limited number of third-party contract research organizations to perform research and development activities on its behalf. These programs could be adversely affected by significant interruption from these providers.
Comprehensive Loss	Comprehensive loss Comprehensive loss includes net loss as well as other changes in stockholders’ equity (deficit) that result from transactions and economic events other than those with stockholders. For the years ended December 31, 2022 and 2021 , there was no difference between net loss and comprehensive loss.
Leases	Leases Prior to January 1, 2022, the Company accounted for leases in accordance with Accounting Standards Codification (“ASC”) 840, Leases. At lease inception, the Company determined if an arrangement was an operating or capital lease. For operating leases, the Company recognized rent expense, inclusive of rent escalations and lease incentives, on a straight-line basis over the lease term. Effective January 1, 2022, the Company adopted ASC 842, Leases (“ASC 842”), and elected to apply the modified retrospective transition approach using the effective date as the initial date of application. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease. A contract is or contains a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. At the lease commencement date, when control of the underlying asset is transferred from the lessor to the Company, the Company classifies a lease as either an operating or finance lease and recognizes a right-of-use (“ROU”) asset and a current and non-current lease liability, as applicable, on the consolidated balance sheet if the lease has a term greater than one year. As permitted under ASC 842, the Company has made an accounting policy election, for all classes of underlying assets, to not recognize ROU assets and lease liabilities for leases having a term of twelve months or less. When it determines the appropriate classification and accounting for a lease arrangement, the Company typically only considers the committed lease term. Options to extend a lease are not included in the Company’s assessment unless there is reasonable certainty that the Company will either renew or not cancel, respectively. At the lease commencement date, the operating lease liability and corresponding ROU asset are recorded at the present value of future lease payments over the expected remaining lease term using the discount rate implicit in the lease, if it is readily determinable, or the Company’s incremental borrowing rate. The Company’s incremental borrowing rate reflects the fixed rate at which the Company could borrow the amount of lease payments in the same currency on a collateralized basis, for a similar term in a similar economic environment. Lease cost for operating leases is recognized on a straight-line basis over the lease term as an operating expense. In addition, certain adjustments to the ROU asset may be required for items such as lease prepayments, incentives received, or initial direct costs. The Company enters into contracts that contain both lease and non-lease components. Non-lease components include costs that do not provide a right-to-use a leased asset but instead provide a service, such as maintenance costs. After its adoption of ASC 842, the Company has elected to combine the lease and non-lease components together as a single lease component for all existing classes of underlying assets. Variable costs associated with the lease, such as maintenance and utilities, are not included in the measurement of right-to-use assets and lease liabilities but rather are expensed when the events determining the amount of variable consideration to be paid have occurred. Upon its adoption of ASC 842 on January 1, 2022 , the Company recorded a lease liability and its corresponding ROU asset based on the present value of lease payments over the remaining lease term. The adoption of ASC 842 resulted in the recognition of an operating lease liability of $ 3.2 million and ROU assets of $ 2.8 million, with the offset attributed to the net derecognition of prepaid rent and the unamortized deferred rent liability, inclusive of tenant improvement allowances on the Company’s balance sheet as of January 1, 2022. The adoption of ASC 842 did no t have a material impact on the Company’s statements of operations and comprehensive loss or statements of cash flows.
Property and Equipment, Net	Property and equipment, net Property and equipment are stated at cost, less accumulated depreciation. Costs of major additions and betterments are capitalized. Maintenance and repairs which do not improve or extend the life of the respective assets are charged to expense as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, which range from five to seven years . Leasehold improvements are amortized over the shorter of the lease term or the estimated useful life of the related asset. When an item is sold or retired, the costs and related accumulated depreciation are eliminated, and the resulting gain or loss, if any, is credited or charged to the consolidated statements of operations. Property and equipment to be disposed of are carried at fair value less costs to sell. The estimated useful lives of the Company’s property and equipment are as follows: Estimated useful life (in years) Laboratory equipment and computer equipment 5 years Furniture 5 - 7 years Leasehold improvements Lesser of asset useful life or lease term
Impairment of Long-Lived Assets	Impairment of long-lived assets The Company accounts for long-lived assets in accordance with ASC Topic 360, Property, Plant, and Equipment (“ASC 360”). ASC 360 requires companies to: (i) recognize an impairment loss only if the carrying amount of a long-lived asset is not recoverable based on its undiscounted future cash flows and (ii) measure an impairment loss as the difference between the carrying amount and the fair value of the asset. The Company tests long-lived assets to be held and used, including property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of assets or asset groups may not be fully recoverable. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the assets, the assets are written down to their fair values. The Company has not recognized any impairment losses during the years ended December 31, 2022 and 2021 .
Fair Value Measurements	Fair value measurements ASC Topic 820, Fair Value Measurement (“ASC 820”), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company’s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier fair value hierarchy that distinguishes among the following: Level 1—Quoted prices in active markets for identical assets or liabilities. Level 2—Observable inputs (other than Level 1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. Level 3—Unobservable inputs that are supported by little or no market activity and that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. The Company has no assets or liabilities classified as Level 3 on its consolidated balance sheets as of December 31, 2022 and 2021. Financial instruments consist of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, accounts payable and accrued expenses and other current liabilities. These financial instruments are stated at their respective historical carrying amounts, which approximate fair value due to their short-term nature.
Deferred Financing Costs	Deferred financing costs The Company capitalizes certain legal, professional accounting and other third-party fees that are directly associated with in-process equity financings as deferred financing costs until such financings are closed. After consummation of the equity financing, these costs are presented in the consolidated balance sheets as a direct reduction from the carrying amount of the respective equity instrument issued. Should an in-process equity financing be abandoned, the deferred offering costs will be expensed immediately as a charge to operating expenses in the consolidated statements of operations. No amounts were recorded as of December 31, 2022 or December 31, 2021 .
Research and Development Costs	Research and development costs Research and development costs are charged to expense as incurred. Research and development costs are comprised of costs incurred in performing research and development activities, including personnel-related costs, stock-based compensation, facilities, research-related overhead, clinical trial costs, contracted services, research-related manufacturing, license fees and other external costs. The Company accounts for nonrefundable advance payments for goods and services that will be used in future research and development activities as expenses when the services have been performed or when the goods have been received.
Accrued Research and Development Expenses	Accrued research and development expenses The Company has entered into various research and development contracts. The payments under these contracts are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes the progress of the research and development activities, including the phase or completion of events, invoices received and contracted costs. Significant judgements and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company’s estimates. The Company’s historical accrual estimates have not been materially different from the actual costs.
Patent costs	Patent costs All patent-related costs incurred in connection with filing and prosecuting patent applications such as direct application fees, and legal and consulting expenses are expensed as incurred due to the uncertainty about the recovery of the expenditure. Patent-related costs are classified as general and administrative expenses within the Company’s consolidated statements of operations.
Redeemable Convertible Preferred Stock	Redeemable convertible preferred stock The Company has classified redeemable convertible preferred stock (“preferred stock”) as temporary equity in the accompanying consolidated balance sheets due to terms that allow for redemption of the shares upon certain events that are outside of the Company’s control. The Company did no t have any preferred stock outstanding as of December 31, 2022 .
Stock-Based Compensation	Stock-based compensation The Company accounts for all share-based payment awards granted to employees and non-employees as stock-based compensation expense at fair value. The Company’s share-based payments include stock options and grants of common stock, including common stock subject to vesting. The measurement date for employee awards is the date of grant, and stock-based compensation costs are recognized as expense over the employees’ requisite service period, which is the vesting period, on a straight-line basis. Prior to the adoption of Accounting Standards Update (“ASU”) No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU No. 2018-07”) on January 1, 2020 , the measurement date for non-employee awards was generally the date the services were completed, resulting in financial reporting period adjustments to stock-based compensation during the vesting terms for changes in the fair value of the awards. Since the adoption of ASU 2018-07, the measurement date for non-employee awards is the date of grant without changes in the fair value of the award. There was no material impact as a result of adopting this new standard. Stock-based compensation costs for non-employees are recognized as expense over the vesting period on a straight-line basis. Stock-based compensation expense is classified in the accompanying consolidated statements of operations based on the function to which the related services are provided. Forfeitures are recorded as they occur. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option-pricing model. Since there is limited historical data of the Company’s share price on the public market, the Company estimates its expected stock volatility based on the historical volatility of a publicly traded set of representative companies and expects to continue to do so until such time as it has adequate historical data regarding the volatility of its own traded stock price. The expected term of the Company’s stock options has been determined utilizing the “simplified” method for awards that qualify as “plain-vanilla” options. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for time periods approximately equal to the expected term of the award. Expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.
Net Loss per Share	Net loss per share Basic net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common stock. Net loss per share attributable to common stockholders is calculated using the two-class method, which is an earnings allocation formula that determines net loss per share for the holders of the Company’s common shares and participating securities. The Company’s preferred stock contained participation rights in any dividend paid by the Company and was deemed to be a participating security. Net loss attributable to common stockholders is allocated to each share on an as-converted basis as if all of the earnings for the period had been distributed. The participating securities did not include a contractual obligation to share in losses of the Company and are not included in the calculation of net loss per share in the periods in which a net loss is recorded. In June 2021, upon the closing of the IPO, all outstanding shares of the Company's preferred stock automatically converted into shares of the Company's common stock. Prior to this conversion, the Company calculated diluted net loss per share using the more dilutive of (a) the two-class method or (b) the if-converted method. The Company allocated earnings first to preferred stockholders based on dividend rights and then to common and preferred stockholders based on ownership interests. The weighted-average number of common shares included in the computation of diluted net loss gives effect to all potentially dilutive common equivalent shares, including outstanding stock options and preferred stock. Common stock equivalent shares are excluded from the computation of diluted net loss per share if their effect is antidilutive. In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders generally the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the years ended December 31, 2022 and 2021 .
Income Taxes	Income taxes The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or the Company’s tax returns. Under this method, deferred tax assets and liabilities are determined based on the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established. The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a “more likely than not” threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are no unrecognized tax benefits included in the Company’s consolidated balance sheet as of December 31, 2022 and 2021 . The Company’s policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized interest or penalties in its Statements of Operations since inception.
Recently Issued Accounting Pronouncements	Recently issued accounting pronouncements From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”), or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s consolidated financial statements upon adoption. Under the Jumpstart Our Business Startups Act of 2012, as amended (the “JOBS Act”), the Company meets the definition of an emerging growth company and has elected the extended transition period for complying with certain new or revised accounting standards pursuant to Section 107(b) of the JOBS Act. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued Accounting Standards Update No. 2019-12 (ASU 2019-12) Simplifying the Accounting for Income Tax . The standard contains several provisions that reduce financial statement complexity including removing the exception to the incremental approach for intra-period tax expense allocation when a company has a loss from continuing operations and income from other items not included in continuing operations. The new guidance is effective for the year beginning January 1, 2022 with optional adoption prior to the effective date, and did not have a material impact to the Company’s consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2022
Accounting Policies [Abstract]
Schedule of Estimated Useful Lives of Property and Equipment	The estimated useful lives of the Company’s property and equipment are as follows: Estimated useful life (in years) Laboratory equipment and computer equipment 5 years Furniture 5 - 7 years Leasehold improvements Lesser of asset useful life or lease term

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2022
Fair Value Disclosures [Abstract]
Schedule of Financial Assets Measured at Fair Value On Recurring Basis	The following tables present information about the Company’s financial assets measured at fair value on a recurring basis (in thousands): December 31, 2022 Assets Total Quoted prices in Significant other observable inputs Significant other Cash equivalents: Money market funds $ 146,870 $ 146,870 $ — $ — Total assets $ 146,870 $ 146,870 $ — $ — December 31, 2021 Assets Total Quoted prices in Significant other observable inputs Significant other Cash equivalents: Money market funds $ 189,488 $ 189,488 $ — $ — Total assets $ 189,488 $ 189,488 $ — $ —

Prepaid Expenses and Other Cu_2

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Summary of Prepaid Expenses and Other Current Assets	Prepaid expenses and other current assets consisted of the following (in thousands): December 31, 2022 2021 Prepaid research and development expenses $ 786 $ 1,549 Prepaid insurance 982 1,397 Prepaid other 321 408 Total $ 2,089 $ 3,354

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2022
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): December 31, 2022 2021 Laboratory and computer equipment $ 1,846 $ 1,541 Leasehold improvements 1,675 1,668 Total property and equipment 3,521 3,209 Less: accumulated depreciation and amortization ( 1,822 ) ( 1,154 ) Property and equipment, net $ 1,699 $ 2,055

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	12 Months Ended
	Dec. 31, 2022
Payables and Accruals [Abstract]
Summary of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities consisted of the following (in thousands): December 31, 2022 2021 Accrued research and development expenses $ 1,356 $ 3,448 Accrued compensation 1,510 1,660 Accrued other 432 618 Operating lease liabilities 889 — Total accrued expenses and other current liabilities $ 4,187 $ 5,726

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Schedule of Common Stock for Potential Conversion of Outstanding Preferred Stock and Exercise of Stock Options	As of December 31, 2022 and 2021, the Company has reserved the following shares of common stock for the potential conversion of outstanding preferred stock and exercise of stock options: December 31, 2022 2021 Options to purchase common stock 3,460,897 2,778,963 Remaining shares reserved for future issuance 5,706,345 5,670,560 Total 9,167,242 8,449,523

Stock-based Compensation (Table

Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Assumptions Used in Black Scholes Option-Pricing Model to Determine Grant Fair Value of Stock Option	The assumptions that the Company used in the Black Scholes option-pricing model to determine the grant date fair value of stock options granted were as follows: December 31, 2022 2021 Risk-free interest rate range%-% 1.89 %- 4.23 % 0.75 %- 1.35 % Dividend yield% 0.0 % 0.0 % Expected life of options (years) 6.0 5.5 - 6.1 Volatility rate range%-% 92.4 %- 93.3 % 93.6 %- 97.1 %
Schedule of Stock Option Activity	The following table summarizes the Company’s stock option activity under the 2012 and 2021 Plan: Number of Weighted average Weighted average Aggregate intrinsic Outstanding as of December 31, 2021 2,778,963 $ 5.80 8.76 $ 17,102 Granted 1,054,559 4.59 Exercised ( 166,867 ) 1.06 Forfeited or cancelled ( 205,758 ) 6.86 Outstanding as of December 31, 2022 3,460,897 $ 5.60 8.23 $ 375 Options vested and exercisable as of December 31, 2022 1,454,830 $ 5.90 7.81 $ 214
Schedule of Stock Based Compensation Expense	Stock-based compensation expense included in the Company’s consolidated statements of operations is as follows (in thousands): December 31, 2022 2021 Research and development $ 1,861 $ 1,154 General and administrative 2,821 2,311 Total stock-based compensation expense $ 4,682 $ 3,465

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Components of Loss Before Provision for Income Taxes	Loss before provision for income taxes was as follows (in thousands): December 31, 2022 2021 United States $ ( 46,034 ) $ ( 42,129 ) Total $ ( 46,034 ) $ ( 42,129 )
Reconciliation of Differences Between Income Taxes Computed at Federal Statutory Rate	The following reconciles the differences between income taxes computed at the federal statutory rate and the provision for income taxes: December 31, 2022 2021 Federal statutory income tax rate 21.0 % 21.0 % State taxes 6.8 % 6.8 % Valuation allowance ( 29.3 )% ( 29.5 )% Tax Credits 2.4 % 2.5 % Stock Based Compensation ( 1.1 )% ( 0.4 )% Other 0.2 % ( 0.4 )% Total —% —%
Schedule of Significant Components of Deferred Tax Assets And Liabilities	Significant components of the Company’s deferred tax assets and liabilities were as follows (in thousands): December 31, December 31, 2022 2021 Deferred tax assets: Net operating loss carryforwards $ 27,219 $ 24,239 Tax credits carryforward 4,613 3,163 Deferred rent — 24 Accrued expenses 366 454 Stock-based compensation 1,255 402 Lease Liability 666 — R&D Capitalization 7,992 — Total deferred tax assets 42,111 28,282 Valuation allowance ( 40,902 ) ( 27,413 ) Deferred tax assets $ 1,209 $ 869 Deferred tax liabilities: Depreciation $ ( 285 ) $ ( 433 ) Prepaid expenses ( 349 ) ( 396 ) Stock-based compensation ( 14 ) ( 40 ) ROU Asset ( 561 ) — Total deferred tax liabilities ( 1,209 ) ( 869 ) Net deferred tax assets $ — $ —
Schedule of Changes in Valuation Allowance for Deferred Tax Assets	Changes in the valuation allowance for deferred tax assets during the years ended December 31, 2022 and 2021 related primarily to the increase in net operating loss carryforwards, capitalized research and development costs, and Research and Development credits and were as follows (in thousands): December 31, December 31, 2022 2021 Valuation allowance at beginning of year $ 27,413 $ 14,983 Increases recorded to income tax provision 13,489 12,430 Valuation allowance at end of year $ 40,902 $ 27,413
Reconciliation of Unrecognized Tax Benefits	The following is a reconciliation of the total amount of unrecognized tax benefits (in thousands): December 31, 2022 2021 Unrecognized benefit at beginning of year $ 582 $ 315 Additions/reductions for tax positions related to the current year 274 267 Unrecognized benefit at end of year $ 856 $ 582

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Computation of Diluted Net Loss per Share Attributable to Common Stockholders	The Company excluded the following shares from the computation of diluted net loss per share attributable to common stockholders as of December 31, 2022 and 2021 because including them would have had an anti-dilutive effect: December 31, 2022 2021 Options to purchase common stock 3,460,897 2,778,963 Unvested shares from early exercises 59,445 169,619

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2022
Leases [Abstract]
Summary of Operating Leases on Consolidated Balance Sheet	The following table summarizes the presentation of the Company's operating leases on its consolidated balance sheet: Leases Balance sheet classification December 31, Assets Operating lease assets Other assets $ 2,066 Liabilities Current Operating lease liabilities Accrued expenses and other current liabilities $ 889 Noncurrent Operating lease liabilities Other long term liabilities 1,560 Total lease liabilities $ 2,449
Components of Lease Cost	The components of lease cost under ASC 842 included in the Company’s consolidated statement of operations for the year ended December 31, 2022 were as follows: Year Ended December 31, Lease Cost Statement of operations classification 2022 Operating lease cost Research and development $ 593 Operating lease cost General and administrative 165 Variable lease cost Research and development 437 Variable lease cost General and administrative 122 Total lease cost $ 1,317
Schedule of Future Minimum Payments Required Under Non-cancellable Operating Leases	Future minimum lease payments under non-cancellable operating leases as of December 31, 2022 are as follows (in thousands): Maturity of lease liabilities Amount 2023 $ 910 2024 883 2025 833 Total lease payments 2,626 Less: interest ( 177 ) Present value of operating lease liabilities $ 2,449

Nature of the Business - Additi

Nature of the Business - Additional Information (Details) $ / shares in Units, $ in Thousands				12 Months Ended
	Jul. 01, 2021 USD ($) $ / shares shares	Jun. 22, 2021 USD ($) $ / shares shares	Jun. 11, 2021	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Subsidiary or Equity Method Investee [Line Items]
Proceeds from issuance of common stock under ESPP				$ 64	$ 0
Stockholders' equity, reverse stock split				1-for-3.4088	1-for-3.4088
Stockholders' equity note, stock split, conversion ratio			0.2934
Accumulated deficit				$ (138,114)	$ (92,053)
Cash and cash equivalents				$ 147,120	$ 189,723
IPO [Member]
Subsidiary or Equity Method Investee [Line Items]
Number of shares issued | shares		7,400,000
Offering price per share | $ / shares		$ 18
Gross proceeds from issuance of common stock		$ 133,200
Proceeds from issuance of common stock under ESPP		$ 121,600
Convertible preferred stock converted to common stock | shares		24,290,875
Convertible preferred stock, shares outstanding | shares		0
Over-Allotment Option [Member]
Subsidiary or Equity Method Investee [Line Items]
Number of shares issued | shares	885,644
Offering price per share | $ / shares	$ 18
Gross proceeds from issuance of common stock	$ 15,900
Proceeds from issuance of common stock under ESPP	$ 14,500

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) Segment shares	Jan. 01, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of operating segments | Segment	1
Deferred financing costs	$ 0
Operating lease liability	2,449,000
Operating lease ROU assets	$ 2,066,000
ASU 2018-07
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2020
Change in accounting principle, accounting standards update, immaterial effect [true false]	true
ASU 2016-02
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022
Change in accounting principle, accounting standards update, immaterial effect [true false]	true
Operating lease liability		$ 3,200,000
Operating lease ROU assets		$ 2,800,000
ASU 2019-12
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Change in accounting principle, accounting standards update, adopted [true false]	true
Change in accounting principle, accounting standards update, adoption date	Jan. 01, 2022
Change in accounting principle, accounting standards update, immaterial effect [true false]	true
Redeemable Convertible Preferred Stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Convertible preferred stock, shares outstanding | shares	0
Maximum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Estimated useful lives	7 years
Minimum [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Estimated useful lives	5 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Estimated Useful Lives of Property Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2022
Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Laboratory Equipment and Computer Equipment
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Furniture | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Furniture | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	7 years
Leasehold Improvements
Property, Plant and Equipment [Line Items]
Estimated useful life	Lesser of asset useful life or lease term

Fair Value Measurement - Schedu

Fair Value Measurement - Schedule of Financial Assets Measured at Fair Value On Recurring Basis (Details) - Recurring - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Assets:
Total assets	$ 146,870	$ 189,488
Money Market Funds
Assets:
Cash equivalents	146,870	189,488
Quoted Prices in Active Markets for Identical Assets (Level 1)
Assets:
Total assets	146,870	189,488
Quoted Prices in Active Markets for Identical Assets (Level 1) | Money Market Funds
Assets:
Cash equivalents	$ 146,870	$ 189,488

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair value of assets, Level 1 to Level 2 transfers, amount	$ 0	$ 0
Fair value of assets, Level 2 to Level 1 transfers, amount	$ 0	$ 0

Prepaid Expenses and Other Cu_3

Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid research and development expenses	$ 786	$ 1,549
Prepaid insurance	982	1,397
Prepaid other	321	408
Total	$ 2,089	$ 3,354

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property Plant And Equipment [Line Items]
Total property and equipment	$ 3,521	$ 3,209
Less: accumulated depreciation and amortization	(1,822)	(1,154)
Property and equipment, net	1,699	2,055
Laboratory and Computer Equipment
Property Plant And Equipment [Line Items]
Total property and equipment	1,846	1,541
Leasehold Improvements
Property Plant And Equipment [Line Items]
Total property and equipment	$ 1,675	$ 1,668

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 668	$ 479

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accrued research and development expenses	$ 1,356	$ 3,448
Accrued compensation	1,510	1,660
Accrued other	432	618
Operating lease liabilities	889
Total accrued expenses and other current liabilities	$ 4,187	$ 5,726

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock - Additional Information (Details) - USD ($)		1 Months Ended	12 Months Ended
	Jun. 22, 2021	Feb. 28, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Series A Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred stock outstanding			0	0	5,817,996
Series B Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Preferred stock outstanding			0	0	55,200,000
Convertible preferred stock conversion ratio			0.10%
Series C Preferred Stock
Temporary Equity [Line Items]
Issuance of Series C preferred stock		21,784,885
Sale of shares, purchase price		$ 3.67
Sale of shares, aggregate purchase price		$ 79,999,980
Redeemable Convertible Preferred Stock
Temporary Equity [Line Items]
Convertible preferred stock converted into shares of common stock	24,290,875
Preferred stock outstanding			0
Preferred stock, voting rights			The holder of each share of Preferred Stock was entitled to one vote for each share of common stock into which it would convert and to vote with the common stock on all matters.
Preferred stock, conversion terms			As of December 31, 2020, the shares of Preferred Stock were convertible into shares of common stock, at the conversion price in effect at the time of such conversion, which was initially one-for-one subject to adjustment for certain potential non-dilutive transactions. The conversion could be initiated by the holder at any time or was mandatory (a) at any time upon the written consent of the holders of a majority of the outstanding shares of the Preferred Stock or (b) immediately upon the closing of a qualified public offering of gross proceeds to the Company of at least $50,000,000. In the event that any holder of shares of Series B Preferred Stock did not purchase the full amount of such holder’s preferred stock tranche obligation, then each share of Series B Preferred Stock held by such holder automatically converted into shares of common stock at a ratio of 1/10th of the applicable conversion ratio.
Convertible preferred stock converted to common stock					1
Threshold gross proceeds from qualified public offering			$ 50,000,000
Percentage of dividends for preferred stock holders			8%
Dividends declared			$ 0

Common Stock - Additional Infor

Common Stock - Additional Information (Details)	12 Months Ended
	Dec. 31, 2022
Equity [Abstract]
Common stock, voting rights	The holders of the common stock are entitled to one vote for each share of common stock held submitted to a vote of stockholders, and there are not any cumulative voting rights.

Common Stock - Schedule of Comm

Common Stock - Schedule of Common Stock for Potential Conversion of Outstanding Preferred Stock and Exercise of Stock Options (Details) - shares	Dec. 31, 2022	Dec. 31, 2021
Class Of Stock [Line Items]
Common stock issuable upon conversion	9,167,242	8,449,523
Remaining Shares Reserved for Future Issuance
Class Of Stock [Line Items]
Common stock issuable upon conversion	5,706,345	5,670,560
Options to Purchase Common Stock
Class Of Stock [Line Items]
Common stock issuable upon conversion	3,460,897	2,778,963

Stock-based Compensation - Addi

Stock-based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Jun. 21, 2021	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of shares of common stock		9,167,242	8,449,523
Weighted average exercise price		$ 5.60	$ 5.80
Compensation expense		$ 4,682	$ 3,465
Weighted-average period		2 years
Weighted-average grant date fair value of stock options granted		$ 3.48	$ 6.87
Total fair value of options vested		$ 5,600	$ 2,100
Unvested Stock Options
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unvested shares related to early exercises of stock options		59,445	169,919
2012 Stock Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Maximum term of options granted		10 years
Vesting period		4 years
Common stock available for future grant		2,732,632
2012 Stock Incentive Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of shares of common stock		6,941,421
2021 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of shares of common stock		5,932,632
Common stock available for future grant		5,706,345
Percentage of number of shares of stock outstanding	5%
2021 Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Percentage of number of shares of stock outstanding	1%
Number of share increase		600,000
Proceeds from ESPP		$ 100
Compensation expense		$ 100
2021 Employee Stock Purchase Plan | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of shares issued		19,374
Weighted average exercise price		$ 3.32
2021 Employee Stock Purchase Plan | Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of shares of common stock	300,000
Number of shares of stock authorized		6,300,000
Current Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of shares of common stock		3,200,000
2012 and 2021 Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized stock based compensation expense		$ 7,400
2012 Shares Made Available 2021 Equity Incentive Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Issuance of shares of common stock		2,732,632

Stock-based Compensation - Assu

Stock-based Compensation - Assumptions Used in Black Scholes Option-Pricing Model to Determine Grant Fair Value of Stock Option (Details) - Stock Option	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate range, minimum	1.89%	0.75%
Risk-free interest rate range, maximum	4.23%	1.35%
Dividend yield	0%	0%
Expected life of options (years)	6 years
Volatility rate range, minimum	92.40%	93.60%
Volatility rate range, maximum	93.30%	97.10%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options (years)		5 years 6 months
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected life of options (years)		6 years 1 month 6 days

Stock-based Compensation - Sche

Stock-based Compensation - Schedule of Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement [Abstract]
Number of shares, beginning balance	2,778,963
Number of shares, Granted	1,054,559
Number of shares, Exercised	(166,867)
Number of shares, Forfeited or cancelled	(205,758)
Number of shares, ending balance	3,460,897	2,778,963
Number of shares, Options vested and exercisable	1,454,830
Weighted average exercise price, beginning balance	$ 5.80
Weighted average exercise price, Granted	4.59
Weighted average exercise price, Exercised	1.06
Weighted average exercise price, Forfeited or cancelled	6.86
Weighted average exercise price, ending balance	5.60	$ 5.80
Weighted average exercise price, Options vested and exercisable	$ 5.90
Weighted average remaining contractual term (in years), balance	8 years 2 months 23 days	8 years 9 months 3 days
Weighted average remaining contractual term (in years), Options vested and exercisable	7 years 9 months 21 days
Aggregate intrinsic value, beginning balance	$ 17,102
Aggregate intrinsic value, ending balance	375	$ 17,102
Aggregate intrinsic value, Options vested and exercisable	$ 214

Stock-based Compensation - Sc_2

Stock-based Compensation - Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 4,682	$ 3,465
Research and Development
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	1,861	1,154
General and Administrative
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 2,821	$ 2,311

Income Taxes - Components of Lo

Income Taxes - Components of Loss Before Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
United States	$ (46,034)	$ (42,129)
Loss before provision for income taxes	$ (46,034)	$ (42,129)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Current provisions for income taxes	$ 0	$ 0
Deferred provisions for income taxes	0	0
Unrecognized tax benefits	856,000	582,000	$ 315,000
Unrecognized tax benefits, income tax penalties and interest expense	0	$ 0
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 100,100,000			$ 4,600,000
Net operating loss carryforwards, expiration year	2037
Federal | Research and Development
Operating Loss Carryforwards [Line Items]
Tax Credit Carryforward, Amount	$ 4,100,000
State
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 98,300,000
Net operating loss carryforwards, expiration year	2042
Tax Credit Carryforward, Amount	$ 1,700,000
Tax credit carry forward expiration year	2037

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Differences Between Income Taxes Computed at Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Federal statutory income tax rate	21%	21%
State taxes	6.80%	6.80%
Valuation allowance	(29.30%)	(29.50%)
Tax Credits	2.40%	2.50%
Stock Based Compensation	(1.10%)	(0.40%)
Other		(0.40%)

Income Taxes - Schedule of Sign

Income Taxes - Schedule of Significant Components of Deferred Tax Assets And Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Deferred tax assets:
Net operating loss carryforwards	$ 27,219	$ 24,239
Tax credits carryforward	4,613	3,163
Deferred rent		24
Accrued expenses	366	454
Stock-based compensation	1,255	402
Lease Liability	666
R&D Capitalization	7,992
Total deferred tax assets	42,111	28,282
Valuation allowance	(40,902)	(27,413)
Deferred tax assets	1,209	869
Deferred tax liabilities:
Depreciation	(285)	(433)
Prepaid expenses	(349)	(396)
Stock-based compensation	(14)	(40)
ROU Asset	(561)
Total deferred tax liabilities	$ (1,209)	$ (869)

Income Taxes - Schedule of Chan

Income Taxes - Schedule of Changes in Valuation Allowance for Deferred Tax Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Valuation Allowance [Line Items]
Valuation allowance at beginning of year	$ 27,413	$ 14,983
Increases recorded to income tax provision	13,489	12,430
Valuation allowance at end of year	$ 40,902	$ 27,413

Income Taxes - Reconciliation_2

Income Taxes - Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Unrecognized benefit at beginning of year	$ 582	$ 315
Additions/reductions for tax positions related to the current year	274	267
Unrecognized benefit at end of year	$ 856	$ 582

Net Loss per Share - Computatio

Net Loss per Share - Computation of Diluted Net Loss per Share Attributable to Common Stockholders (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Options to Purchase Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of EPS	3,460,897	2,778,963
Unvested Shares from Early Exercises
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of EPS	59,445	169,619

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - Premises - Massachusetts - ft²	1 Months Ended		12 Months Ended
	Jul. 31, 2021	Aug. 31, 2018	Dec. 31, 2022
Lessee Lease Description [Line Items]
Existence option to extend operating lease	true
Description of option to extend operating lease			In July 2021, the Company entered into the second amendment of the lease and expanded the office space by approximately 5,531 square feet (the “Expansion Premises”), and extended the maturity date to December 31, 2025 for both the Original Premises and Expansion Premises.
Lease expiration date		Oct. 31, 2023
Number of square feet expanding	5,531
Total rentable area		14,636

Leases - Additional Information

Leases - Additional Information (Details) $ in Millions	1 Months Ended		12 Months Ended
	Jul. 31, 2021 ft²	Aug. 31, 2018 ft²	Dec. 31, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Operating lease, weighted average remaining lease term			3 years
Operating lease, weighted average discount rate			5%
Operating lease, payments | $			$ 0.8
Premises | Massachusetts
Lessee, Lease, Description [Line Items]
Total rentable area		14,636
Lease expiration date		Oct. 31, 2023
Number of square feet expanding	5,531
Operating lease extended maturity date	Dec. 31, 2025
Description of option to extend operating lease			In July 2021, the Company entered into the second amendment of the lease and expanded the office space by approximately 5,531 square feet (the “Expansion Premises”), and extended the maturity date to December 31, 2025 for both the Original Premises and Expansion Premises.
Existence option to extend operating lease	true
Increase in annual rent percentage	3%

Leases - Summary of Operating L

Leases - Summary of Operating Leases on Consolidated Balance Sheet (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Assets
Operating lease assets	$ 2,066
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets
Liabilities
Operating lease liabilities, Current	$ 889
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Accrued expenses and other current liabilities
Operating lease liabilities, Noncurrent	$ 1,560
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other long term liabilities
Total lease liabilities	$ 2,449

Leases - Components of Lease Co

Leases - Components of Lease Cost (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Lessee, Lease, Description [Line Items]
Total lease cost	$ 1,317
Research and Development
Lessee, Lease, Description [Line Items]
Operating lease cost	593
Variable lease cost	437
General and Administrative
Lessee, Lease, Description [Line Items]
Operating lease cost	165
Variable lease cost	$ 122

Leases - Schedule of Future Min

Leases - Schedule of Future Minimum Payments Required Under Non-cancellable Operating Leases (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Lessee, Operating Lease, Liability, to be Paid [Abstract]
2023	$ 910
2024	883
2025	833
Total lease payments	2,626
Less: interest	(177)
Present value of operating lease liabilities	$ 2,449

Employee Benefit Plans - Additi

Employee Benefit Plans - Additional information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2022 USD ($)
Share-Based Payment Arrangement [Abstract]
Contributions by employer	$ 0.3

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Subsequent Event $ in Millions	Jan. 19, 2023 USD ($)
Subsequent Event [Line Items]
Percentage of workforce reduction and preclinical efforts	70%
Minimum
Subsequent Event [Line Items]
Employee severance and benefit costs	$ 2.5
Maximum
Subsequent Event [Line Items]
Employee severance and benefit costs	$ 3